Core Insights - Venus Concept Inc. has received FDA 510(k) clearance for its new product, Venus NOVA, marking a significant milestone in the company's R&D strategy [1][3] - Venus NOVA is designed to provide a comprehensive solution for non-invasive body, face, and skin treatments, integrating multiple advanced technologies [2][3] Product Features - Venus NOVA incorporates Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF) combined with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology [2][4] - The platform aims to enhance body contouring, muscle conditioning, skin treatments, and reduce wrinkles and cellulite [2] Strategic Initiatives - The launch of Venus NOVA aligns with the company's turnaround strategy initiated in 2023 and the Venus AI strategic initiative, focusing on innovation and customer partnerships [3] - The product is expected to support the growing demand for aesthetic treatments, particularly for patients using GLP-1 medications, with an anticipated increase to over 32 million users globally by 2030 [3] Market Positioning - Venus NOVA is positioned to penetrate the multi-billion-dollar body and skin market, contributing to the company's long-term growth profile [3] - The product will be available in the U.S. starting December 2025, with global rollouts planned for 2026 and beyond [6] Support Programs - The Venus Jumpstart Program will provide a 30-day roadmap for advanced clinical education and marketing enablement to ensure successful integration of Venus NOVA into existing practices [4][5]

Core Viewpoint - Venus Concept Inc. has successfully reduced its outstanding debt by exchanging $11.48 million of subordinated convertible notes for preferred stock, improving its financial position significantly [1][2]. Financial Position - The total debt obligations of Venus Concept are now approximately $30.1 million, reflecting a 24% reduction from $39.7 million as of December 31, 2024 [1]. Strategic Initiatives - The debt-to-equity exchange is part of Venus Concept's strategy to enhance financial flexibility and support long-term growth and profitability [2]. - The partnership with Madryn Asset Management is viewed as invaluable in advancing the company's transformation plan [2]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [4].

Core Points - Venus Concept Inc. will release its third quarter financial results for fiscal year 2025 on November 13, 2025, before market opening [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day to discuss the results and answer questions [2] - A replay of the conference call will be available for two weeks for those unable to participate live [3] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products [4] - The company operates in over 60 countries and has 9 direct markets, with a diverse product portfolio including various aesthetic device platforms and hair restoration systems [4] - Venus Concept is supported by prominent healthcare industry growth equity investors [4]

Company Overview - Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products for aesthetic and hair restoration [4] - The company operates in over 60 countries and has 9 direct markets, showcasing its extensive reach in the industry [4] - Venus Concept's product portfolio includes various aesthetic device platforms and hair restoration systems, such as NeoGraft® and the ARTAS iX® Robotic Hair Restoration system [4] Financial Results Announcement - The company will release its second quarter fiscal year 2025 financial results after market close on August 14, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and answer questions [2] - For those unable to attend, a replay of the call will be available for two weeks, and a webcast will be archived on the company's investor relations website [3] Investor Relations - Investor relations contact for Venus Concept is managed by ICR Healthcare, with Mike Piccinino, CFA, as the point of contact [5]

Core Insights - Venus Concept Inc. has successfully exchanged $6.5 million of subordinated convertible notes for 325,651 shares of Series Y preferred stock, resulting in a 14% reduction in total debt obligations from $39.7 million to approximately $34.3 million [1][2] Group 1: Financial Position - The debt exchange improves the Company's balance sheet and provides financial flexibility for ongoing strategic initiatives, including the divestiture of the Venus Hair business [2] - The total debt reduction reflects the Company's commitment to optimizing its capital structure [2] Group 2: Management Commentary - The CEO of Venus Concept emphasized the importance of the partnership with Madryn Asset Management in achieving financial flexibility and supporting the Company's transformation plan [2] - Madryn Asset Management expressed support for the management team and the Company's efforts to return to growth [2] Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4] - The product portfolio includes various aesthetic device platforms and hair restoration systems, backed by prominent healthcare industry investors [4]

Core Viewpoint - Venus Concept Inc. has successfully closed a registered direct offering, raising approximately $1.15 million, with potential additional proceeds of up to $2.3 million from unregistered short-term warrants [1][3]. Group 1: Offering Details - The company sold 434,720 shares of common stock at a price of $2.65 per share [1]. - Concurrently, unregistered short-term warrants were issued to purchase up to 869,440 shares at the same exercise price, which are immediately exercisable and will expire in eighteen months [1][3]. - The gross proceeds from the offering are approximately $1.15 million before fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes [3]. Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [7]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7].

Core Points - Venus Concept Inc. has announced a registered direct offering of 434,720 shares of common stock at a price of $2.65 per share, with expected gross proceeds of approximately $1.15 million [1][3] - The company will also issue unregistered short-term warrants to purchase up to 869,440 shares at the same exercise price, potentially generating an additional $2.3 million if fully exercised [1][3] - The offering is expected to close around June 9, 2025, pending customary closing conditions [1] Offering Details - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The shares are being offered under a "shelf" registration statement effective since November 1, 2024, and a final prospectus supplement will be filed with the SEC [4] - The unregistered short-term warrants are offered in a private placement and have not been registered under the Securities Act [5] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a range of minimally invasive and non-invasive products across over 60 countries [7] - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7]

Core Viewpoint - Venus Concept Inc. reported a decline in financial performance for the first quarter of 2025, with total revenue decreasing by 22% year-over-year, attributed to challenging market conditions and timing of new system adoptions [5][10]. Financial Results Summary - Total revenue for Q1 2025 was $13.6 million, down from $17.5 million in Q1 2024, reflecting a decrease of $3.8 million or 21.9% [5][6]. - Revenue breakdown showed a 29.3% decrease in international revenue and a 16.5% decrease in U.S. revenue [6]. - Revenue from products—systems decreased by 25%, and lease systems revenue also saw a 25% decline [6][7]. - Gross profit for Q1 2025 was $8.8 million, a decrease of 25% compared to Q1 2024, with a gross margin of 64.2% [7][10]. - Operating expenses decreased by 6% year-over-year to $18.3 million, driven by reductions in general and administrative, selling and marketing, and research and development expenses [8][9]. - The company reported a GAAP net loss of $12.4 million for Q1 2025, compared to a net loss of $9.8 million in Q1 2024 [10][11]. Management Commentary - The CEO emphasized solid execution despite a challenging environment and indicated a focus on managing cash burn and making targeted investments for long-term growth [3][4]. - The company enhanced its balance sheet with a new bridge loan amendment and two equity capital transactions, indicating validation from investors regarding its potential value creation [3][4]. Cash Position and Debt - As of March 31, 2025, the company had cash and cash equivalents of $3.2 million and total debt obligations of approximately $35.5 million, a decrease from $39.7 million at the end of 2024 [11][12]. - The company is currently not providing full-year 2025 financial guidance due to ongoing evaluations of strategic alternatives and potential trade disruptions [12]. Conference Call Details - Management will host a conference call to discuss the quarterly results, providing an opportunity for questions and answers [13].